Dyadic International (DYAI)
Produces proteins and enzymes through C1 and Dapibus platforms for life sciences, food, and bio-industrial uses.
Something off on this page? Send us feedback.
Commercializes C1 and Dapibus microbial platforms that produce recombinant proteins and enzymes for life sciences, food and nutrition, and bio-industrial applications. The organization is shifting from technology development toward commercial operations.
C1 and Dapibus platforms develop and produce recombinant proteins and enzymes. C1, a microbial expression system formerly used for industrial enzymes and other proteins, retained pharmaceutical-use rights after the industrial business was sold; Dapibus targets non-therapeutic life sciences, food and nutrition, and bio-industrial applications. The operation is shifting from technology development toward commercial execution, with US operations and a satellite office in the Netherlands.
Commercialization depends on third parties and is shaped by capital needs, intellectual-property exposure, regulation, and Nasdaq listing standards. The business retains a broader biopharmaceutical platform opportunity alongside current non-therapeutic commercial inputs.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Target |
|---|---|---|---|
| Oct 23, 2025 | H.C. Wainwright | Target | $3 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $3.1M · Total debt $5.0M · Total assets $6.5M · Shareholders' equity −$2.4M
- Revenue
- $961.1K
- Operating income
- −$2.1M
- Net income
- −$2.1M
No dividends on record.
| Institutions37 holders · as of Mar 31, 2026 | 14.11% | 5.14M shares | |
| Insiders9 holders · as of Feb 17, 2026 | 21.37% | 7.79M shares | |
| Strategic holders1 holder · as of Jul 24, 2026 | 11.62% | 4.23M shares | |
| Otherremainder | 52.90% | 19.28M shares |
36.44M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Mark A. Emalfarb1Insiderdirector, 10 percent owner, officer: CEO | 18.32% | 6.68M | 13Gfiled Feb 17, 2026 ↗ |
Francisco Trust under agreement dated February 28, 19962Strategic10 percent owner | 11.62% | 4.33M | 13Gfiled Jul 24, 2026 ↗ |
Apis Capital Advisors, LLCInstitution | 3.49% | 1.27M | 13Fas of Mar 31, 2026 |
Vanguard Capital Management LLCInstitution | 2.55% | 928,233 | 13Fas of Mar 31, 2026 |
Chapin Davis, Inc.Institution | 2.44% | 888,004 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
- Mark A. Emalfarb's transaction reports restate only vehicles that traded; the 2026 ownership statement (6.68M) is used instead.
- Francisco Trust under agreement dated February 28, 1996's transaction reports restate only vehicles that traded; the 2026 ownership statement (4.33M) less the 95.4K net shares sold since is used instead.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 24, 2026 | Francisco Trust under agreement dated February 28, 1996 | 10 percent owner | −2,616 | $1.21 |
| Jul 23, 2026 | Francisco Trust under agreement dated February 28, 1996 | 10 percent owner | −54,760 | $1.30 |
| Jul 22, 2026 | Francisco Trust under agreement dated February 28, 1996 | 10 percent owner | −38,016 | $1.33 |
| Mar 8, 2024 | Francisco Trust under agreement dated February 28, 1996 | 10 percent owner | +558,659 | $1.79 |
| Jan 7, 2025 | Francisco Trust under agreement dated February 28, 1996 | 10 percent owner | −15,000 | $2.01 |
- Ginkgo Bioworks
Cell programming and autonomous laboratory services
- Codexis
Engineered enzymes for scalable therapeutics manufacturing
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Dyadic International | $0.5470 | +3.05% | $19.1M | — | — | 5.5 | +107.4% |
| Ginkgo Bioworks | $7.08 | +0.57% | $459.2M | — | — | 4.1 | −59.4% |
| Codexis | $1.45 | −1.69% | $158.7M | — | — | 2.0 | −2.7% |
| Median | — | — | 3.1 | −31.0% |